Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Pfizer says COVID vaccine is highly effective against Delta variant

Published 24/06/2021, 19:40
Updated 24/06/2021, 19:45
© Reuters. FILE PHOTO: A person walks past a Pfizer logo amid the coronavirus disease (COVID-19) pandemic in the Manhattan borough of New York City, New York, U.S., April 1, 2021. REUTERS/Carlo Allegri

© Reuters. FILE PHOTO: A person walks past a Pfizer logo amid the coronavirus disease (COVID-19) pandemic in the Manhattan borough of New York City, New York, U.S., April 1, 2021. REUTERS/Carlo Allegri

By Maayan Lubell

JERUSALEM (Reuters) - The Pfizer-BioNTech ‮>‬PFE.N‮<‬ vaccine is highly effective against the Delta variant of COVID-19, a Pfizer (NYSE:PFE) official in Israel said on Thursday.

First identified in India, Delta is becoming the globally dominant variant of the coronavirus, according to the World Health Organization.

"The data we have today, accumulating from research we are conducting at the lab and including data from those places where the Indian variant, Delta, has replaced the British variant as the common variant, point to our vaccine being very effective, around 90%, in preventing the coronavirus disease, COVID-19," Alon Rappaport, Pfizer's medical director in Israel, told local broadcaster Army Radio.

A study by researchers from the University of Texas together with Pfizer and BioNtech and published this month by Nature journal found that antibodies elicited by the vaccine were still able to neutralize all tested variants, including Delta, albeit at reduced strength.

"We continue to synthesize viruses in our labs and with collaborators as we see new variants emerge so we can conduct testing to obtain the most information we can about our vaccine’s impact on neutralisation of emerging strains," a Pfizer spokesperson said in an email to Reuters.

Other recent studies have also shown the vaccine is likely to provide high protection against the variant.

Israel has one of the world's most advanced vaccination campaigns largely based on the Pfizer-BioNTech shot. Sharon Alroy-Preis, head of public health at Israel's Health Ministry, said that Israel still lacks enough data to provide insight into vaccine effectiveness against the Delta variant.

"We are collecting the data now. We are only now seeing the first cases of the Delta variant in Israel - about 200 of those - so we will know more soon," she told reporters on Wednesday.

An analysis by Public Health England (PHE), where the Delta variant is more widespread, found that both the Pfizer/BioNTech and AstraZeneca (NASDAQ:AZN) vaccines provide more than 90% protection against hospitalization from the Delta variant.

In Israel, more than half the 9.3 million population has received both Pfizer shots and a steep drop in cases has prompted authorities to lift most coronavirus restrictions.

© Reuters. FILE PHOTO: A person walks past a Pfizer logo amid the coronavirus disease (COVID-19) pandemic in the Manhattan borough of New York City, New York, U.S., April 1, 2021. REUTERS/Carlo Allegri

But confirmed cases have risen in the past few days and health authorities have urged parents to vaccinate their 12-to 15-year-olds, who were made eligible this month.

Alroy-Preis said around 65% of Israel's population was protected against COVID-19, either by vaccination or by recovering from the disease, a figure she said was still far from providing "herd immunity."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.